This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "QoL Data With Neoadjuvant Ipi & Nivo in Resectable Stage III Melanoma - 36-Week Data From the NADINA Trial"

57 views
June 14, 2024

Chapters

Neoadjuvant Therapy & NADINA Trial Overview

00:00

Adverse Events & Patient Experience

02:41

Quality of Life Data & Conclusions

04:56

Comments 0
Login to view comments. Click here to Login